Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1AN | Q9NWT6 | 9/20 | 0.67 |
| ▸ | ODC1 | P11926 | 4/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14315437 | 1.00 | HIF1AN (0.67) | HIF1ANODC1NFKB1NFKB2RELA | |
| SCHEMBL31376188 | 0.94 | HIF1AN (0.75) | HIF1ANODC1NFKB1NFKB2RELA | |
| SCHEMBL31376262 | 0.94 | HIF1AN (0.75) | HIF1ANODC1NFKB1NFKB2RELA | |
| SCHEMBL31376261 | 0.94 | ODC1 (0.75) | HIF1ANODC1NFKB1NFKB2RELA | |
| SCHEMBL31376189 | 0.91 | ODC1 (0.64) | HIF1ANODC1NFKB1NFKB2RELA | |
| SCHEMBL31376169 | 0.91 | HIF1AN (0.65) | HIF1ANODC1NFKB1NFKB2RELA | |
| Xanthohumol C SCHEMBL14249680 | 0.90 | NFKB1 (0.65) | HIF1ANODC1NFKB1NFKB2RELA | |
| Xanthohumol C SCHEMBL30066955 | 0.90 | NFKB1 (0.65) | HIF1ANODC1NFKB1NFKB2RELA | |
| Xanthohumol C SCHEMBL12961704 | 0.90 | NFKB1 (0.65) | HIF1ANODC1NFKB1NFKB2RELA | |
| SCHEMBL31376266 | 0.89 | ACHE (0.70) | HIF1ANODC1NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956199-B2 | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders | Aigner, Ludwig (DE) | 2018-05-01 | — | — | US | disclosed |
| EP-3202398-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | Aigner, Ludwig (DE) | 2017-08-09 | — | — | EP | disclosed |
| US-20170128411-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | Aigner, Ludwig (AT) | 2017-05-11 | — | — | US | disclosed |
| EP-2720693-B1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | AIGNER LUDWIG (AT) | 2017-03-08 | — | — | EP | disclosed |
| US-9527860-B2 | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders | Aigner, Ludwig (AT) | 2016-12-27 | — | — | US | disclosed |
| US-20140349919-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | COUILLARD-DESPRES, Sébastien (AT) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128411-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | BDNF, MAP2, DCX | HIF1AN 1645/4885ODC1 4119/4885NFKB1 3784/4885 |
| US-20140349919-A1 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS | BDNF, MAP2, DCX | HIF1AN 1645/4885ODC1 4119/4885NFKB1 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.